Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood.v94.2.673.414k30_673_683PMID 10397734
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multipin peptide synthesis at the micromole scale using 2-hydroxyethyl methacrylate grafted polyethylene supports.

  2009cited by this paper
• Generation of T cell clones binding F(ab′)2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy

  2005cited by this paper
• The extent of the human germline T-cell receptor V beta gene segment repertoire

  2004cited by this paper
• Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.

  1999cited by this paper
• Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.

  1998cited by this paper
• A class I MHC-restricted recall response to a viral peptide is highly polyclonal despite stringent CDR3 selection: implications for establishing memory T cell repertoires in "real-world" conditions.

  1998cited by this paper
• Immunogenicity and cross‐reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma

  1998cited by this paper
• Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.

  1998cited by this paper
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.

  1998cited by this paper
• In‐vivo immune responses to idiotypic VH complementarity‐determining region 3 peptide vaccination in B‐cell non‐Hodgkin's lymphoma

  1998cited by this paper
• Diagnosis, prognosis, and standard treatment of multiple myeloma.

  1997cited by this paper
• The human T cell receptor repertoire utilized in response to HBsAg.

  1997cited by this paper
• Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.

  1997cited by this paper
• Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.

  1997cited by this paper
• Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients

  1997cited by this paper
• Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.

  1997cited by this paper
• T cells recognize the VH complementarity‐determining region 3 of the idiotypic protein of B cell non‐Hodgkin's lymphoma

  1997cited by this paper
• Expanded CD4+ and CD8+ T cell clones in elderly humans.

  1997cited by this paper
• T‐cell receptor CDR3 size distribution analysis to evaluate specific T‐cell response to cancer vaccines

  1997cited by this paper
• A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors

  1997cited by this paper
• Idiotype‐specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets

  1997cited by this paper
• Graft-versus-myeloma effect: proof of principle.

  1996cited by this paper
• A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma

  1996cited by this paper
• Modulation of anti‐idiotypic immune response by immunization with the autologous M‐component protein in multiple myeloma patients

  1996cited by this paper
• Mitogens, superantigens, and nominal antigens elicit distinctive patterns of TCRB CDR3 diversity.

  1996cited by this paper
• Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation.

  1996cited by this paper
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper
• Idiotype‐induced T cell stimulation requires antigen presentation in association with HLA‐DR molecules

  1996cited by this paper
• Autotransplants in multiple myeloma: what have we learned?

  1996cited by this paper
• Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

  1996cited by this paper
• Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.

  1995cited by this paper
• Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies.

  1995cited by this paper
• T-cell repertoire diversity and clonal expansions in normal and clinical samples.

  1995cited by this paper
• Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.

  1995cited by this paper
• High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting.

  1995cited by this paper
• Low‐dose recombinant interleukin‐2 therapy in advanced multiple myeloma

  1995cited by this paper
• Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients.

  1995cited by this paper
• High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma.

  1994cited by this paper
• Oligoclonality of tumor-infiltrating lymphocytes from human melanomas.

  1994cited by this paper
• Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.

  1994cited by this paper
• The treatment of multiple myeloma.

  1994cited by this paper
• Histoanalytical study of the cellular infiltrate in the tuberculin reaction

  1993cited by this paper
• Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells.

  1993cited by this paper
• Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas

  1993cited by this paper
• An experimentally validated panel of subfamily‐specific oligonucleotide primers (Vα1‐w29/Vβ1‐w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction

  1992cited by this paper
• Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.

  1992cited by this paper
• Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex.

  1991cited by this paper
• Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.

  1990cited by this paper
• Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status.

  1988cited by this paper
• Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

  1979cited by this paper
• A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

  1975cited by this paper
• Myeloma proteins as tumor-specific transplantation antigens.

  1972cited by this paper
• Cell-bound myeloma proteins on the surface of myeloma cells: potential targets for the immune system.

  1972cited by this paper

• Advances and challenges in anti-cancer vaccines for multiple myeloma

  2024cites this paper
• Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties

  2024cites this paper
• Multiple Myeloma and Dendritic Cell Vaccines

  2021cites this paper
• A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients.

  2021cites this paper
• The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy

  2021cites this paper
• Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma

  2018cites this paper
• Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.

  2017cites this paper
• Dendritic Cell Therapies for Hematologic Malignancies

  2017cites this paper
• Immune Therapies in Multiple Myeloma

  2016cites this paper
• Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma

  2015cites this paper
• Immunotherapy strategies in multiple myeloma.

  2014cites this paper
• Cellular Immunotherapy Using Dendritic Cells in Multiple Myeloma: New Concept to Enhance Efficacy

  2013influential citation
• Immunologic microenvironment and personalized treatment in multiple myeloma

  2013cites this paper
• CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma

  2012cites this paper
• Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions

  2012cites this paper
• Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients

  2012cites this paper
• Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes

  2012cites this paper
• Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.

  2012cites this paper
• Multiple myeloma patients at peripheral blood stem cell harvest: restricted usage of TCR beta variable families.

  2011cites this paper
• Induction of Cellular Immune Responses in Patients With Stage-I Multiple Myeloma After Vaccination With Autologous Idiotype-pulsed Dendritic Cells

  2011cites this paper
• Stem cell transplant and idiotypic vaccination for B-cell malignancies.

  2011cites this paper
• Myeloma of T Cells from Patients with Multiple Activity and Decreases CD45RA Expression Lenalidomide Enhances Antigen-Specific

  2011cites this paper
• Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma

  2011cites this paper
• Optimizing dendritic cell‐based immunotherapy in multiple myeloma: intranodal injections of idiotype‐pulsed CD40 ligand‐matured vaccines led to induction of type‐1 and cytotoxic T‐cell immune responses in patients

  2010cites this paper
• Idiotype vaccines for human B-cell malignancies.

  2010cites this paper
• The role of idiotype-specific immunity in antigen receptor diversity

  2010cites this paper
• Idiotype‐pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

  2009cites this paper
• Melan-A/MART1 Analog Peptide Triggers Anti-myeloma T-cells Through Crossreactivity With HM1.24

  2009influential citation
• Curriculum Vitae

  2009cites this paper
• Novel Immunotherapies

  2009cites this paper
• Identification of HLA‐A2 restricted T‐cell epitopes within the conserved region of the immunoglobulin G heavy‐chain in patients with multiple myeloma

  2008cites this paper
• Immunomodulation against leukemias and lymphomas: a realistic future treatment?

  2008cites this paper
• A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

  2008cites this paper
• Anti-idiotype antibodies in cancer treatment

  2007cites this paper
• Antigen‐Specific T‐Cell Immunity in Multiple Myeloma Patients is Restored Following High‐Dose Therapy: Implications for Timing of Vaccination

  2007cites this paper
• Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient‐specific tumour idiotype protein or idiotype (VDJ)‐derived class I‐restricted peptides

  2007cites this paper
• Polyclonal Immunoglobulin E Levels Are Correlated with Hemoglobin Values and Overall Survival in Patients with Multiple Myeloma

  2007cites this paper
• Idiotype Vaccination Strategies in Myeloma: How to Overcome a Dysfunctional Immune System

  2007cites this paper
• Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.

  2007cites this paper
• Long-term Idiotype Vaccination Combined with Interleukin-12 (IL-12), or IL-12 and Granulocyte Macrophage Colony-Stimulating Factor, in Early-Stage Multiple Myeloma Patients

  2007cites this paper
• Immune therapies.

  2007cites this paper
• Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.

  2007cites this paper
• Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma

  2006cites this paper
• Current therapeutic uses of lenalidomide in multiple myeloma

  2006cites this paper
• Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells.

  2006cites this paper
• Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.

  2006cites this paper
• The use of thalidomide in myeloma therapy as an effective anticancer drug.

  2006cites this paper
• Vaccines for tumour prevention

  2006cites this paper
• Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

  2006cites this paper
• Activated γδ T cells express the natural cytotoxicity receptor natural killer p44 and show cytotoxic activity against myeloma cells

  2006cites this paper
• Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation

  2006cites this paper
• Current status of immunotherapy in B cell malignancies.

  2006cites this paper
• Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T cells for adoptive immunotherapy

  2006cites this paper
• Active immunotherapy of multiple myeloma.

  2006cites this paper
• Heat shock protein-based cancer vaccines.

  2006cites this paper
• Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research.

  2006cites this paper
• Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma

  2005cites this paper
• [Hematopoietic stem cell transplantation in multiple myeloma].

  2005cites this paper
• Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.

  2005cites this paper
• Vaccine strategies to treat lymphoproliferative disorders.

  2005cites this paper
• Role of allogeneic stem cell transplantation in multiple myeloma

  2005cites this paper
• Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1‐like regulatory T cells

  2005cites this paper
• DC-based immunotherapy of B-cell malignancies.

  2004cites this paper
• Treatment of multiple myeloma.

  2004cites this paper
• Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy

  2004cites this paper
• DCs in lymphoma--biology and therapeutic aspects.

  2004cites this paper
• An update of novel therapeutic approaches for multiple myeloma

  2004cites this paper
• Therapeutic idiotype vaccines in B lymphoproliferative diseases

  2004cites this paper
• Immunobiology of haematological malignant disorders: the basis for novel immunotherapy protocols.

  2004cites this paper
• Stem cell transplantation for multiple myeloma.

  2004cites this paper
• Immunotherapeutic approaches for hematologic malignancies.

  2004cites this paper
• Multiple myeloma

  2004cites this paper
• Molecular Monitoring of Minimal Residual Disease in Patients with Multiple Myeloma

  2004cites this paper
• The role of idiotype vaccines in the treatment of human B-cell malignancies

  2004cites this paper
• Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma

  2004cites this paper
• Part II: Vaccines for haematological malignant disorders.

  2004cites this paper
• Post‐transplantation tumour load in bone marrow, as assessed by quantitative ASO‐PCR, is a prognostic parameter in multiple myeloma

  2004cites this paper
• High-Dose Therapy and Stem Cell Transplantation

  2004cites this paper
• Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion.

  2004cites this paper
• Graft vs. Host Disease and Graft vs. Myeloma Effect after Non-myeloablative Allogeneic Transplantation

  2004cites this paper
• A novel recombinant bispecific single-chain antibody, bscWue-1 × CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells

  2004cites this paper
• Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models

  2004cites this paper
• B7+ T Cells in Myeloma: an Acquired Marker of Prior Chronic Antigen Presentation

  2004cites this paper
• T cells in myeloma

  2003cites this paper
• Immunotherapy in multiple myeloma: current strategies and future prospects

  2003cites this paper
• CMRF44+ Dendritic Cells from Peripheral Blood Stem Cell Harvests of Patients with Myeloma as Potential Cellular Vectors for Idiotype Vaccination

  2003cites this paper
• Cancer vaccines: between the idea and the reality

  2003cites this paper
• Anti‐idiotype vaccines

  2003cites this paper
• Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte–macrophage colony‐stimulating factor and interleukin 2 in a myeloma model

  2003cites this paper
• Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.

  2003cites this paper
• Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.

  2003cites this paper
• Clonal Cytotoxic T Cells in Myeloma

  2003cites this paper
• Cellular Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation: Experimental Strategies and Clinical Experiences

  2003cites this paper
• A review of the cytokine network in multiple myeloma

  2003cites this paper
• Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma

  2003cites this paper
• Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA.

  2003cites this paper
• Dendritic Cell-based Immunotherapy for the Treatment of Hematological Malignancies

  2003cites this paper
• Non-Radiolabelled PCR Consensus Primers and Automatic Sequencing Enable Rapid Identification of Tumor-Specific VH CDR3 in Aggressive B-Cell Malignancies

  2003cites this paper
• Novel therapeutic approaches for multiple myeloma

  2003cites this paper
• Recent Developments in Hematopoietic Stem Cell Transplantation for Multiple Myeloma

  2003cites this paper